In contrast, the difference between codon 13 and KRAS wild-type in terms of OS in studies of CRC patients with anti-EGFR treatment were nonsignificant (pooled HR = 1.57, 95% CI: 0.98–2.51, I2 = 61.0%, P = .06). This evidence concerns the gene KRAS and colorectal carcinoma.